Value of biomarkers in predicting mortality in older medical emergency department patients: a Dutch prospective study

Noortje Zelis,1,2 Robin Hundscheid,1 Jacqueline Buijs,1 Peter W De Leeuw,1,2,3 Maarten TM Raijmakers,4 Sander MJ van Kuijk,5 Patricia M Stassen

ABSTRACT

Objective Older emergency department (ED) patients are at high risk of mortality, and it is important to predict which patients are at highest risk. Biomarkers such as lactate, high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), D-dimer and procalcitonin may be able to identify those at risk. We aimed to assess the discriminatory value of these biomarkers for 30-day mortality and other adverse outcomes.

Design Prospective cohort study. On arrival of patients, five biomarkers were measured. Area under the curves (AUCs) and interval likelihood ratios (LRs) were calculated to investigate the discriminatory value of the biomarkers.

Setting ED in the Netherlands.

Participants Older (≥65 years) medical ED patients, referred for internal medicine or gastroenterology.

Primary and secondary outcome measures 30-day mortality was the primary outcome measure, while other adverse outcomes (intensive care unit/medium care unit admission, prolonged length of hospital stay, loss of independent living and unplanned readmission) were the composite secondary outcome measure.

Results The median age of the 450 included patients was 79 years (IQR 73–85). In total, 51 (11.3%) patients died within 30 days. The AUCs of all biomarkers for prediction of mortality were sufficient to good, with the highest AUC of 0.73 for hs-cTnT and NT-proBNP. Only for the highest lactate values, the LR was high enough (29.0) to be applicable for clinical decision making, but this applied to a minority of patients. The AUC for the composite secondary outcome (intensive and medium care admission, length of hospital stay >7 days, loss of independent living and unplanned readmission within 30 days) was lower, ranging between 0.58 and 0.67.

Conclusions Although all five biomarkers predict 30-day mortality in older medical ED patients, their individual discriminatory value was not high enough to contribute to clinical decision making.

Trial registration number NCT02946398; Results.

INTRODUCTION

Background Biomarkers such as lactate, high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), D-dimer and procalcitonin (PCT) are frequently used to diagnose and estimate the severity of specific diseases. They are able to detect underlying conditions or diseases that are often present in older patients (≥65 years) who visit the emergency department (ED). These include tissue hypoperfusion, myocardial injury, heart failure, thromboembolism and infections. Although several studies report that these markers are associated with adverse outcomes and predict short-term mortality,1–11 most of these were performed in relatively young ED patients.1–4 6–8 10–12 in selected ED patients with infection or sepsis1–3 10–12 or in patients with non-specific complaints.5 It is also noteworthy that in these studies, biomarkers were only measured when the ED physician deemed this to be indicated, because they were not routinely measured.4 8 Consequently, the true discriminatory value of these biomarkers for prediction of adverse outcomes in ED patients remains unknown.

Strengths and limitations of this study

► This was a prospective study in which biomarkers were measured in all older patients, irrespective of the problem they presented with.
► The results of these tests were not reported back, except for lactate, and therefore did not influence the doctors.
► We calculated not only the total predictive ability of the biomarkers but also interval likelihood ratios, as we hypothesised that extreme values do not add to decision making in the same way as values that are intermediate.
► The limitations of the study are, besides the single-centre design, that not all consecutive patients were included because physicians prioritised in providing care at busy moments.
Importance

Older patients who visit the ED are at a substantial risk of adverse outcomes including short-term mortality, intensive or medium care unit (ICU/MCU) admission, functional decline and readmissions. During the ED visit, it is crucial to establish which older patients are at highest risk, but this remains a challenging task. It is possible that biomarkers are helpful in establishing this risk.

Goals of this investigation

The aim of this prospective study was to assess the discriminatory value of arterial lactate, hs-cTnT, NT-proBNP, D-dimer and PCT for 30-day mortality and other adverse outcomes (ICU/MCU admission, prolonged length of hospital stay (LOS) in the hospital, loss of independent living and unplanned readmission) when measured routinely in older medical ED patients.

METHODS

Study design, setting and selection of participants

This study is part of the RISE UP Study, a prospective multicentre study conducted at two EDs in the Netherlands. The study protocol of this study was published online. This part of the study took place in Zuyderland Medical Centre (MC), a large teaching hospital in the south of the Netherlands, because biomarkers were measured in patients included in this site only. Patients were included if they visited the ED between July 2016 and February 2017, were 65 years old or older, were examined and treated by an internist or gastroenterologist and provided written informed consent. Exclusion criteria were earlier participation in the study and inability to speak Dutch, German or English.

Measurements

At the moment of routine blood sampling at the ED, an additional arterial blood gas sample and two venous blood samples were drawn. Lactate levels were measured immediately in arterial blood samples on the RAPIDPoint 500 system and were available for the attending physician. Venous blood samples were centrifuged at 1800 g for 10 min, and plasma was stored in a freezer at −20°C. D-dimer levels were measured within 4 weeks after presentation using the Sysmex CS-2100i system. Plasma was analysed for hs-cTnT, NT-proBNP and PCT levels within 3–4 months by the Cobas 8000 modular analyser. Results of all biomarkers, except those for lactate, were blinded for all healthcare providers and only available to the investigators. If one of these four biomarkers was ordered by the attending physician as part of normal clinical practice, a different blood sample was analysed, and the results were reported as usual.

All data were collected from electronic medical records. The following data were retrieved on arrival at the ED: age, sex, living situation, data on comorbidity according to the Charlson Comorbidity Index and triage category (using the Manchester Triage System). The abovementioned five biomarkers were retrieved as well.

Outcomes

Thirty-day all-cause mortality was used as primary endpoint for the discriminatory value of the biomarkers. The secondary endpoint was a composite endpoint of ICU/MCU admission, prolonged LOS (>7 days), loss of independent living and unplanned readmission within 30 days after discharge. LOS was retrieved for patients who were admitted immediately following the ED visit. Loss of independent living was defined as discharge to a nursing home/hospice or with palliative care in previously community-dwelling patients.

Data regarding the outcomes were collected by checking the electronic medical files, which are connected to the municipal administration and by contacting the general practitioner if necessary.

Patient and public involvement

No patient involved.

Analysis

The sample size available for this study depended on a prospective cohort study, the RISE UP Study, which provided data on 450 patients. For logistic regression analysis, at least 10 event per candidate predictor are needed, according to prediction modelling guidelines. We assumed that the mortality rate would be around 11%. Therefore, the inclusion of 450 patients provided more than sufficient observations for our primary objective.

We performed descriptive analyses of baseline characteristics, biomarker levels and outcomes on the observed data without imputation of missing values.
Continuous variables are reported as means with SD or medians with IQRs and categorical variables as proportions. Comparisons between the survivor and non-survivor groups were made using unpaired t-tests for continuous variables with Gaussian distribution, Mann-Whitney tests for continuous non-Gaussian data and Pearson’s χ² or Fisher’s exact test for categorical data.

We calculated the discriminatory value of the biomarkers for the primary and secondary outcomes by constructing the area under the curves (AUCs) with 95% CIs on the available data. Accuracy of the AUCs was considered excellent if between 0.9 and 1.0, very good if 0.8 and 0.9, good if 0.7 and 0.8, sufficient if 0.6 and 0.7 and bad if between 0.5 and 0.6.20

We divided the biomarkers into five groups ranging from lowest to highest values. Next, interval likelihood ratios (LRs) and mortality percentages were calculated within these groups. We considered high LRs (>10) and low LR (<0.1) as being of additional value to clinical decision making.21

We used univariable logistic regression to compute the ORs with 95% CIs for the biomarkers with respect to 30-day mortality.

As a subanalysis, we evaluated the discriminatory ability of a combination of biomarkers. For this purpose, we used logistic regression with backwards elimination using a p value of 0.10 for removal and determined the discriminatory ability of this new model by calculating the AUC with 95% CI.

Logistic regression analyses were performed on data after imputation of missing values to allow for the inclusion of all patients. Sensitivity analyses were performed to assess the impact of missing data on our results by comparing the results after imputation to complete case analysis. Missing values of biomarkers were imputed using stochastic regression imputation with predictive mean matching (online supplemental table S1). All biomarkers were tested for collinearity using Pearson’s correlation coefficient and for influential outliers using Cook’s distance. Linearity was visually checked for all biomarkers and log transformed or dichotomised depending on the relationship with the outcome. For dichotomisation, the optimum cut-off value was chosen based on the values being closest to the upper left corner of the AUC. If two values were equally distanced, Youden’s Index was used.
All data were analysed using IBM SPSS Statistics for Windows, V.24.0 (IBM), and p values <0.05 were considered statistically significant.

RESULTS

Characteristics of study subjects

For all 450 patients included during the study period, follow-up was complete (figure 1). The median age was 79 years (IQR 73–85), and 52% were men. In total, 51 (11.3%) patients died within 30 days after the ED visit, and 201 (44.7%) met the composite endpoint. The patients who died were older than those who survived (p value <0.001, table 1). Non-survivors more frequently experienced the composite endpoint (n=37, 72.5%) compared with the survivors (n=164, 41.1%; p value <0.001).

Main results

Biomarkers

Four biomarkers, hs-cTnT, NT-proBNP, D-dimer and PCT, were above the reference range in most patients (66.4%, 86.0%, 78.0% and 79.8%, respectively), whereas for lactate, this was true in 25.6% of patients. The highest values of the biomarkers were more often present in non-survivors, whereas the lowest values were more often present in survivors, but there was a large overlap between the non-survivors and survivors (table 1 and figure 2).

Diagnostic accuracy of the biomarkers

The AUCs for prediction of 30-day mortality were sufficient for lactate and PCT with values of 0.68 (95% CI 0.59 to 0.77) and 0.67 (95% CI 0.60 to 0.75), respectively (table 2). The AUCs of the other biomarkers were good with the highest AUCs for hs-cTnT and NT-proBNP with a value of 0.73 (95% CI 0.66 to 0.80) for both. The AUCs of the biomarkers for the composite endpoint were mostly sufficient but lower than for mortality (ranging between 0.58 and 0.67).

LRs increased with higher biomarker values, except PCT (table 3). Most of the biomarkers had maximum LRs between 3.2 (PCT) and 4.7 (NT-proBNP), except lactate. We retrieved a maximum LR of 29.0 when lactate was between 6.0 and 10.0 mmol/L with a mortality percentage of 80.0%. The maximum LRs were, however, only applicable to a limited number of patients (n=5). The lowest LRs for all biomarkers were less variable but ranging between 0.3 (NT-proBNP) and 0.6 (lactate).

Univariable logistic regression analysis

Lactate and D-dimer were dichotomised, and hs-cTnT, NT-proBNP and PCT were logarithmically transformed because they were not linearly associated with 30-day
mortality. The optimum cut-off value was >1.5 mmol/L for lactate and >3000 µg/L for D-dimer. None of the biomarkers were highly correlated. In the univariable logistic regression analysis, all biomarkers were strong predictors of 30-day mortality with p values of <0.001 (table 4).

**Subanalysis of combining biomarkers**

In order to assess the discriminatory value of multiple biomarkers, we developed a model through backwards elimination in the multiple logistic regression analysis. PCT did not contribute significantly to the model (p value 0.51) and was therefore removed (table 4). This resulted in a model consisting of lactate, hs-cTnT, NT-proBNP and D-dimer. The AUC for prediction of 30-day mortality of these four biomarkers combined was 0.82 (95% CI 0.76 to 0.87).

**DISCUSSION**

To the best of our knowledge, this is the first study evaluating the discriminatory value of lactate, hs-cTnT, NT-proBNP, D-dimer and PCT, when measured routinely, for predicting clinical outcome in older (≥65 years) medical ED patients. We conclude that these five biomarkers are predictive of 30-day mortality with the best discriminator values for hs-cTnT and NT-proBNP (AUCs of 0.73). However, we observed a large overlap in biomarker values between the survivor and non-survivor group, resulting in suboptimal LRs. Overall, the predictive ability of the biomarkers for the composite endpoint turned out to be lower than for the primary endpoint.

We showed that lactate, hs-cTnT, NT-proBNP, D-dimer and PCT are sufficient to good predictors of 30-day mortality.

### Table 3  Interval likelihood ratios (LRs) for the biomarkers

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Mortality</th>
<th>Observed mortality (%)</th>
<th>N</th>
<th>LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactate (mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1.0</td>
<td>5 (10.9)</td>
<td>62 (18.7)</td>
<td>67</td>
<td>0.6</td>
</tr>
<tr>
<td>&gt;1.0–2.0</td>
<td>20 (43.5)</td>
<td>197 (59.3)</td>
<td>217</td>
<td>0.7</td>
</tr>
<tr>
<td>&gt;2.0–4.0</td>
<td>14 (30.4)</td>
<td>65 (19.6)</td>
<td>79</td>
<td>1.6</td>
</tr>
<tr>
<td>&gt;4.0–6.0</td>
<td>3 (6.5)</td>
<td>7 (2.1)</td>
<td>10</td>
<td>3.1</td>
</tr>
<tr>
<td>&gt;6.0–10.0</td>
<td>4 (8.7)</td>
<td>1 (0.3)</td>
<td>5</td>
<td>29.0</td>
</tr>
<tr>
<td>hs-cTnT (ng/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–20</td>
<td>9 (18.4)</td>
<td>184 (48.9)</td>
<td>193</td>
<td>0.4</td>
</tr>
<tr>
<td>&gt;20–40</td>
<td>13 (26.5)</td>
<td>102 (27.1)</td>
<td>115</td>
<td>1.0</td>
</tr>
<tr>
<td>&gt;40–60</td>
<td>11 (22.4)</td>
<td>44 (11.7)</td>
<td>55</td>
<td>1.9</td>
</tr>
<tr>
<td>&gt;60–100</td>
<td>8 (16.3)</td>
<td>28 (7.4)</td>
<td>36</td>
<td>2.2</td>
</tr>
<tr>
<td>&gt;100</td>
<td>8 (16.3)</td>
<td>18 (4.8)</td>
<td>26</td>
<td>3.4</td>
</tr>
<tr>
<td>NT-proBNP (ng/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–500</td>
<td>6 (12.2)</td>
<td>150 (40.0)</td>
<td>156</td>
<td>0.3</td>
</tr>
<tr>
<td>&gt;500–1000</td>
<td>7 (14.3)</td>
<td>69 (18.4)</td>
<td>76</td>
<td>0.8</td>
</tr>
<tr>
<td>&gt;1000–2500</td>
<td>9 (18.4)</td>
<td>67 (17.9)</td>
<td>76</td>
<td>1.0</td>
</tr>
<tr>
<td>&gt;2500–10000</td>
<td>14 (28.6)</td>
<td>68 (18.1)</td>
<td>82</td>
<td>1.6</td>
</tr>
<tr>
<td>&gt;10000</td>
<td>13 (26.5)</td>
<td>21 (5.6)</td>
<td>34</td>
<td>4.7</td>
</tr>
<tr>
<td>D-dimer (µg/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–1000</td>
<td>8 (17.0)</td>
<td>149 (41.1)</td>
<td>157</td>
<td>0.4</td>
</tr>
<tr>
<td>&gt;1000–2500</td>
<td>12 (25.5)</td>
<td>112 (31.1)</td>
<td>124</td>
<td>0.8</td>
</tr>
<tr>
<td>&gt;2500–5000</td>
<td>12 (25.5)</td>
<td>56 (15.6)</td>
<td>68</td>
<td>1.6</td>
</tr>
<tr>
<td>&gt;5000–10000</td>
<td>9 (19.1)</td>
<td>30 (8.3)</td>
<td>39</td>
<td>2.3</td>
</tr>
<tr>
<td>&gt;10000</td>
<td>6 (12.8)</td>
<td>13 (3.6)</td>
<td>19</td>
<td>3.6</td>
</tr>
<tr>
<td>PCT (ng/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–0.1</td>
<td>10 (20.4)</td>
<td>166 (44.3)</td>
<td>176</td>
<td>0.5</td>
</tr>
<tr>
<td>&gt;0.1–0.5</td>
<td>16 (32.7)</td>
<td>137 (36.5)</td>
<td>153</td>
<td>0.9</td>
</tr>
<tr>
<td>&gt;0.5–1.0</td>
<td>6 (12.2)</td>
<td>21 (5.6)</td>
<td>27</td>
<td>2.2</td>
</tr>
<tr>
<td>&gt;1.0–5.0</td>
<td>12 (24.5)</td>
<td>29 (7.7)</td>
<td>41</td>
<td>3.2</td>
</tr>
<tr>
<td>&gt;5.0</td>
<td>5 (10.2)</td>
<td>22 (5.9)</td>
<td>27</td>
<td>1.7</td>
</tr>
</tbody>
</table>

hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCT, procalcitonin.
mortality (AUCs ranging from 0.67 to 0.73) and sufficient predictors of the composite endpoint (AUCs ranging from 0.58 to 0.67) in older medical ED patients. Other studies showed the same results.6–8 10 11 22–28 However, in most of these studies, biomarkers were not measured routinely. Moreover, two studies showed that mortality was lowest in patients in whom biomarkers were not ordered during normal clinical practice.4 7 These findings show that the predictive value of biomarkers measured in all older ED patients differs from that measured only when indicated by the physician. We think that the predictive values we found for the biomarkers are more reflective of their true prognostic ability than when measured on indication.

Despite the fact that the five biomarkers were overall predictive of 30-day mortality, on an individual level, we found a large overlap in biomarker values between survivors and non-survivors. The overlap in biomarker values was most prominent in patients with non-extreme values. Especially in this group of patients, it is likely that the prognosis of the patient is less evident to the treating physician. Therefore, an estimation of prognosis provided by a biomarker is highly important. However, the discriminatory value of biomarker values in these patients was low as illustrated by the moderate LRs. In a US Study in patients with trauma, clinically meaningful contribution to decision making only occurred at lactate levels of >9mmol/L,29 which was only present in a minority of patients. In our study, lactate had an important LR of 29 when between 6 and 10mmol/L, which was only applicable to five patients. For the secondary composite endpoint, the discriminatory value of the biomarkers was even lower (ranging between 0.58 and 0.67). Therefore, we conclude that the five biomarkers do not contribute to clinical decision making.

Besides their discriminatory ability, the extra costs for determining the biomarkers should be taken into account. In more than 90% of patients (75% for lactate), biomarkers were not ordered by the physician (online supplemental table S2). Measuring these biomarkers on a routine basis will therefore lead to direct and indirect costs because abnormal test results (26%–86% of results were outside the reference range in our study) will undoubtedly lead to additional diagnostic tests, like CT scans.

In the multivariable analysis, stepwise elimination resulted in a new model consisting of four biomarkers, lactate, hs-cTnT, NT-proBNP and D-dimer, which yielded an AUC of 0.82. This discriminatory ability was, however, not better than that of the recently developed RISE UP Score (AUC 0.83), which consists of age, vital signs and four routine laboratory tests, albumin, blood urea nitrogen, lactate dehydrogenase and bilirubin.20 The RISE UP Score was developed in the same patient sample and has the advantage of using inexpensive variables, which are collected in routine ED care making the score feasible for use in older ED patients. In addition, we recently showed that adding these biomarkers to the RISE UP model only minimally improved the AUC of the model by 0.03.31 The limited added discriminatory ability and the expected extra costs support our conclusion that routinely determined biomarkers are not beneficial for prediction of mortality in older ED patients.

While we showed that biomarkers, measured at the ED visit, predict 30-day mortality, it is unknown whether assessment of these parameters will influence clinical decision making, outcome, well-being and medical costs. For this reason, the impact of biomarkers on clinical practice and patient-related outcome measures may be an interesting subject for future studies.

Our study has some limitations. First, due to moments of crowding of the ED, it was not possible to include every possible candidate, as physicians had to give priority to providing emergency care. We detected no evidence for selection bias but cannot exclude it either.17 In addition, we only measured biomarker values immediately after arrival at the ED. It is possible that serial biomarker measurement may have yielded different information and a different predictive ability.
In conclusion, the biomarkers such as lactate, hs-TnT, NT-proBNP, D-dimer and PCT, when measured routinely, have predictive value with regard to short-term mortality and other adverse outcomes in older medical ED patients, but given the large overlap in values between those with and without adverse outcomes, they are unlikely to individually contribute to clinical decision making. Therefore, we conclude that routine measurement of these parameters is not recommended.

REFERENCES


Supplemental File

Supplementary tables

**Supplemental Table S1. Overview imputed values**

<table>
<thead>
<tr>
<th>Imputed variable</th>
<th>Total (n=450)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactate</td>
<td>72 (16.0)</td>
</tr>
<tr>
<td>Hs-cTnT</td>
<td>25 (5.6)</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>26 (5.8)</td>
</tr>
<tr>
<td>D-dimer</td>
<td>43 (9.6)</td>
</tr>
<tr>
<td>PCT</td>
<td>26 (5.8)</td>
</tr>
</tbody>
</table>

Hs-cTnT, high-sensitivity cardiac Troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCT, procalcitonin

**Supplemental Table S2. Biomarkers ordered by the physician**

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>% of patients*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactate</td>
<td>25.8</td>
</tr>
<tr>
<td>Hs-cTnT</td>
<td>7.6</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>8.7</td>
</tr>
<tr>
<td>D-dimer</td>
<td>5.1</td>
</tr>
<tr>
<td>PCT</td>
<td>0.0</td>
</tr>
</tbody>
</table>

Hs-cTnT, high-sensitivity cardiac Troponin T; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; PCT, procalcitonin

*Represents the proportion of patients for whom the biomarker was ordered by the physician